Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Prathap Reddy, P.
- Attention Deficit Hyperactivity Disorder: A Neurological Cramp
Abstract Views :262 |
PDF Views:1
Authors
D. Rajesh Kumar
1,
P. Prathap Reddy
2,
V. Sai Krishna
2,
B. Manikanta
2,
D. Naga Jyothi
2,
K. Samrajyam
2
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
2 Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
2 Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 44-49Abstract
Attention deficit hyperactivity disorder (ADHD) is also referred as attention deficit disorder (ADD) is a neurological disorder usually found in children of elementary school age. This condition begins in childhood. There are mainly three types of ADHD include predominantly inattentive presentation, predominantly hyperactive-impulsive presentation and combined presentation. Both genetic and environmental factors contribute to development of ADHD .The neurotransmitters dopamine and norepinephrine are also involved in occurrence of ADHD. There's no specific test for diagnosis of ADHD. Standard treatments for ADHD in children include stimulant medications, education, training and counseling.Keywords
ADHD, ADD, Dopamine, Norepinephrine, Stimulant Medications.References
- Gilliam M, Stockman M, Malek M, Sharp W, Greenstein D, et al. Developmental trajectories of the corpus callosum in attention deficit/hyperactivity disorder. Biol Psychiatry. 2011 May 1;69(9):839-46. Epub 2011 Jan 17. PMID: 21247556.
- Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2010 Mar;33(1):159-80. Review. PubMed PMID: 20159345; PubMed Central PMCID: PMC 2847260.
- Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009 Jul;126(1):51- 90. Epub 2009 Jun 9. Review. PubMed PMID: 19506906.
- Shaw P, Gornick M, Lerch J, Addington A, Seal J, et al. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007 Aug;64(8):921-31. PMID: 17679637.
- Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011 Dec 4;44(1):78- 84. doi: 10.1038/ng.1013. PMID: 22138692.
- Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2012 Feb;169(2):195-204. PMID: 22420048.
- National Institutes of Health (NIH) Consensus Statement on the Diagnosis and Treatment of ADHD. NIH Consensus Statement. 1998;16:1-37.
- Le Fever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999;89:1359-1364.
- Zito JM, Safer DJ, dos Reis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
- Hoagwood K, Kelleher KJ, Feil M, et al. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:198-206.
- MTA Group. Moderators and mediators of treatment response for children with ADHD: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088-1096.
- Amen DG. Change Your Brain, Change Your Life. New York, NY: Three Rivers Press; 1998.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Levy, F., Hay, D.A., McStephen, M., Wood, C., & Waldman, I. (1997). Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 737-744.
- Millichap JG, Yee MM. The diet factor in attention deficit/hyperactivity disorder. Pediatrics. 2012 Feb;129(2):330- 7. Epub 2012 Jan 9. Review. PubMed PMID: 22232312.
- Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):86-97.e8. PMID: 22176942.
- Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148:56477.
- A Review on Alzheimer's Disease
Abstract Views :355 |
PDF Views:3
Authors
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, IN
3 SIMS College of Pharmacy, Guntur, Andhra Pradesh, IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, IN
3 SIMS College of Pharmacy, Guntur, Andhra Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 59-63Abstract
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. There are three stages of the condition mild, moderate and severe. The symptoms are also varies from stage to stage. Some of the causes of this disease includes age, family history, Down's syndrome and vascular disease. Mainly it occurs due to presence of extracellular amyloid plaques and intracellular neurofibrillary tangles. Diagnosis can be done by using CT scan, MRI scan and Cognitive tests. Cholinesterase inhibitors and partial glutamate antagonists are used for the treatment. It can be prevented by performing some of activities like reading, writing and learning foreign languages.Keywords
Alzheimer's Disease, Dementia, Down's Syndrome, Amyloid Plaques and Cholinesterase Inhibitors.References
- Berchtold NC, Cotman CW. Evolution in the Conceptualization of Dementia and Alzheimer's Disease: Greco-Roman Period to the 1960s. Neurobiol. Aging. 1998;19(3):173-89.
- Brookmeyer R., Gray S., Kawas C.. Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset. American Journal of Public Health. 1998;88(9):1337-42.
- Brookmeyer R, Johnson E, Ziegler-Graham K, MH Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia. 2007 [Retrieved 2008-06- 18];3(3):186-91.
- World population prospects: the 2006 revision, highlights [PDF]. 2007 [Retrieved 2008-08-2
- Nistor M. Alpha- and Beta-secretase Activity as a Function of Age and Beta-amyloid in Down Syndrome and Normal Brain. Neurobiol Aging. 2007;28(10):1493-1506.
- Lott IT, Head E. Alzheimer Disease and Down Syndrome: Factors in Pathogenesis. Neurobiol Aging. 2005;26(3):383-89
- Hardy J, Allsop D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease. Trends Pharmacol. Sci.. 1991;12(10):383-88.
- Polvikoski T. Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein. N Engl J Med. 1995;333(19):1242-47.
- Games D. Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein. Nature. 1995;373(6514):523-27.
- Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein and Alzheimer's Disease. J Neurosci. 1996;16(18):5795-811.
- Hsiao K. Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science. 1996;274(5284):99-102.
- Lauren J. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers. Nature. 2009; 457 (7233): 1128-32.
- Nikolaev A, McLaughlin T, O'Leary D, Tessier-Lavigne M. APP Binds DR6 to Cause Axon Pruning and Neuron Death via Distinct Caspases. Nature. 19 February 2009;457(7232):981-989. Goedert M, Spillantini MG, Crowther RA. Tau Proteins and Neurofibrillary Degeneration. Brain Pathol. 1991;1(4):279-86.
- Francis PT, Palmer AM, Snape M, Wilcock GK. The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress. J. Neurol. Neurosurg. Psychiatr. 1999;66(2):137-47.
- Shen ZX. Brain Cholinesterases: II. The Molecular and Cellular Basis of Alzheimer's Disease. Med Hypotheses. 2004;63(2):308- 21.
- Iqbal K. Tau Pathology in Alzheimer Disease and Other Tauopathies. Biochim Biophys Acta. 2005;1739(2-3):198-210.
- Chun W, Johnson GV. The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death. Front Biosci. 2007;12:733-56
- Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy Body Pathology in Alzheimer's Disease. J Mol Neurosci. 2001;17(2):225-32
- Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases. Neuromolecular Med.. 2003;4(1-2):21-36.
- Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse Formation and Function is Modulated by the Amyloid Precursor Protein. J. Neurosci. 2006;26(27):7212-21.
- Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of Amyloid Precursor Protein and its Fragments in Regulating Neural Activity, Plasticity and Memory. Prog. Neurobiol.. 2003; 70(1):1-32.
- Bermejo-Pareja F, Benito-Leon J, Vega S, Medrano MJ, Roman GC. Incidence and subtypes of dementia in three elderly populations of central Spain. J. Neurol. Sci.. 2008; 264(1-2):63- 72.
- Di Carlo A. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002; 50(1):41-8.
- Andersen K. Gender Differences in the Incidence of AD and Vascular Dementia: The Eurodem Studies. Eurodem Incidence Research Group. Neurology. 1999;53(9):1992-7.
- Tejada-Vera, B. (2013). Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
- Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer Disease in the US population: Prevalence Estimates Using the 2000 census. Arch. Neurol. 2003;60(8):1119-22.
- "Profiles of General Demographic Characteristics, 2000 Census of Population and Housing, United States" (PDF). U.S. Census Bureau. 2001. Archived from the original on 19 August 2008. Retrieved 2008-08-27.
- Ferri CP. Global Prevalence of Dementia: A Delphi Consensus Study. Lancet. 2005;366(9503):2112-7.
- World Health Organization (2006). Neurological Disorders: Public Health Challenges. Switzerland: World Health Organization. pp. 204-207.
- Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing, 2012, volume 41, supplement 3, pages iii 35-40. Reprint of original 1972 paper published online
- Alzheimer's Association. Cognitive assessment. Information on Alzheimer's disease for healthcare professionals. Published online, accessed November 1st, 2013.
- NICE. Diagnosis and assessment of dementia. In: Dementia: Supporting people with dementia and their carers in health and social care, NICE clinical guideline. London, UK: National Institute for Health and Care Excellence, November 2006.
- Alzheimer's Society. The mini mental state examination (MMSE). Fact sheet published online, accessed November 1st, 2013.
- Medicinenet.com Prevention
- www.nhs.uk